Provided by Tiger Trade Technology Pte. Ltd.

Lexeo Therapeutics

3.38
-0.0400-1.17%
Post-market: 3.380.00000.00%19:30 EDT
Volume:3.05M
Turnover:10.38M
Market Cap:277.32M
PE:-2.95
High:3.59
Open:3.44
Low:3.28
Close:3.42
52wk High:10.99
52wk Low:2.98
Shares:82.05M
Float Shares:51.23M
Volume Ratio:1.20
T/O Rate:5.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1457
EPS(LYR):-1.8634
ROE:-46.76%
ROA:-27.59%
PB:1.18
PE(LYR):-1.81

Loading ...

Lexeo Therapeutics Reports Unregistered Equity Issuances Post-Merger

TIPRANKS
·
Yesterday

Lexeo Therapeutics Issues USD 3 Million in Unregistered Shares in Mantle Merger

Reuters
·
Yesterday

Lexeo Therapeutics Price Target Maintained with a $15.00/Share by Leerink Partners

Dow Jones
·
Sep 23

Press Release: Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX(TM) for Program Designed to Treat Friedreich Ataxia

Dow Jones
·
Sep 23

Lexeo Therapeutics to Join Stifel Virtual Cardiometabolic Forum Fireside Chat

Reuters
·
Sep 23

Lexeo Therapeutics enter into agreement to acquire Mantle Therapeutics

TIPRANKS
·
Sep 22

Lexeo Therapeutics expands FA pipeline with Mantle acquisition

TIPRANKS
·
Sep 22

Lexeo Therapeutics Agrees to Buy Mantle Therapeutics for up to $21.3 Million

Reuters
·
Sep 22

Lexeo Therapeutics, - Maintains Cash Runway Guidance into 2028

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics Enters into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics, - Deal Includes up to $13 Mln in Milestone Payments, Total Potential $21.30 Mln

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics, - to Pay $8.30 Mln Upfront to Mantle Shareholders

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

GlobeNewswire
·
Sep 22

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

GlobeNewswire
·
Sep 02

Lexeo Therapeutics Releases Corporate Presentation Outlining Cardiac Gene Therapy Pipeline, AAVrh.10 Platform

Reuters
·
Aug 12

Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate

Benzinga Earnings
·
Aug 12

Lexeo Net Loss Narrows to $25.9 Million in Q2 FY26; R&D Expenses Rise to $19 Million

Reuters
·
Aug 12

Press Release: Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Dow Jones
·
Aug 12

Lexeo Therapeutics, - Lx2020 Holds Rmat, Orphan Drug, and Fast Track Designations from FDA

THOMSON REUTERS
·
Aug 05

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Lx2020 for the Treatment of Pkp2 Arrhythmogenic Cardiomyopathy

THOMSON REUTERS
·
Aug 05